CAS 1204313-51-8|Icotinib Hydrochloride

Introduction:Basic information about CAS 1204313-51-8|Icotinib Hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameIcotinib Hydrochloride
CAS Number1204313-51-8Molecular Weight427.881
Density/Boiling Point/
Molecular FormulaC22H22ClN3O4Melting Point/
MSDS/Flash Point/

Names

NameIcotinib Hydrochloride
SynonymMore Synonyms

Icotinib Hydrochloride BiologicalActivity

DescriptionIcotinib Hydrochloride (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q.
Related CatalogResearch Areas >>Cancer
Target

EGFR:5 nM (IC50)

EGFRL861Q

EGFRL858R/T790M

EGFRL858R

EGFRT790M

In VitroIncubation with Iconitib at 0.5 μM results in kinase activity inhibition of 91%, 99%, 96%, 61% and 61%, respectively. Iconitib inhibits the proliferation of A431 and BGC-823 A549, H460 and KB cell lines with IC50s of 1, 4.06, 12.16, 16.08, 40.71 μM. When profiled with 88 kinases, Icotinib only shows meaningful inhibitory activity to EGFR and its mutants. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation (IC50=45 nM) in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation[1].
In VivoIcotinib exhibits potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug is well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment. Icotinib inhibits tumor growth at a rate of 25.2%, 45.6% and 51.5% in the A431 cell line groups; 3.4%, 25.9% and 31.0% in the A549 cell line groups; 49.4%, 52.6% and 67.4% in the H460 cell line groups, and 30.3%, 36.4% and 46.5% in the HCT8 cell line groups, at 30, 60 and 120 mg/kg/dose, respectively[1].
Kinase AssayIn the in vitro kinase assays, 2.4 ng/μL EGFR protein is mixed with 32 ng/μL Crk in 25 μL kinase reaction buffer containing 1 μM cold ATP and 1 μCi32P-γ-ATP. The mix is incubated with Icotinib at 0, 0.5, 2.5, 12.5 or 62.5 nM on ice for 10 min followed by incubation at 30°C for 20 min. After quenching with SDS sample buffer at 100°C for 4 min, the protein mix is resolved by electrophoresis in a 10% SDS-PAGE gel. The dried gel is then exposed to detect radioactivity. Quantification is performed by software[1].
Cell AssayCells (1000/well) are seeded into 96-well plates in RPMI-1640 medium containing 10% FBS and grown in a 5% CO2 incubator at 37°C. After 24 h, cells are treated with Icotinib at 0, 0.78, 1.56, 3.125, 6.25, 12.5 or 25 μM for 96 h. Cell proliferation is calculated by subtracting the mean absorbance value on day 0 from the mean absorbance value on day 4[1].
Animal AdminMice: The effect of three doses of Icotinib (30, 60, and 120 mg/kg/dose p.o. qd) on antitumor activity and survival is determined in mice bearing A431, A549, H460 and HCT8 tumor xenografts. Taxol (30 mg/kg/dose i.p. once a week) is employed in these experiments as a positive control group[1].
References

[1]. Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76(2):177-82.

Chemical & Physical Properties

Molecular FormulaC22H22ClN3O4
Molecular Weight427.881
Exact Mass427.129883
PSA74.73000
LogP4.03410
InChIKeyPNNGXMJMUUJHAV-UHFFFAOYSA-N
SMILESC#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1.Cl
Storage condition2-8℃

Synonyms

Icotinib HCl
[1,4,7,10]Tetraoxacyclododecino[2,3-g]quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-, hydrochloride (1:1)
BPI-2009H
UNII-JTD32I0J83
CS-0918
N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine hydrochloride (1:1)
Icotinib (Hydrochloride)
CAS 1312445-63-8|NVP-BKM120 (Hydrochloride)
CAS 1068976-42-0|3-Ethyl-5-fluoro-1H-pyrrolo[2,3-b]pyridine
Recommended......
TOP